Biomedical subjects
Publications and source records attributed to F X Kleber.
Account is given of a patient with legionnaires' disease to highlight the increasing significance of this affection. The typical symptoms are described. Under doxycyclin at high dosage (200 mg/day) the patient became afebrile within 36 hours with concurrent improvement of his general condition. Distinct regression of the pulmonary infiltrate was seen within five days.
Although partial gastrectomy does not, as a rule, greatly impair the absorption of ethambutol by tuberculous patients, subtotal or total gastrectomy may reduce it by 40--60 per cent. Rifampicin and isoniazid are almost completely absorbed; but postprandial administration of rifampicin may be preferable in these cases. In the presence of anacidity absorption of isoniazid is slowed down but not reduced quantitatively. To estimate the degree to which absorption is impaired the drug levels in the blood after oral and intravenous administration should be determined over two consecutive days.
Elevated pulmonary vascular resistances occur to a variable degree in patients with chronic congestive heart failure (CHF). These might be caused by increased levels of endogenous vasoconstrictors, defective endothelial vasodilatory mechanisms or structural vascular abnormalities. To determine the contribution of defective endothelial mediated vasodilation, we tested 10 patients with CHF due to coronary artery disease (n = 4) or dilated cardiomyopathy (n = 5), and congenital corrected transposition of the great arteries (n = 1) (median pulmonary artery pressure 36 mmHg, range of pulmonary vascular resistance 0.94-10.7 WE). Patients were in median functional class NYHA III, median left ventricular ejection fraction was 21%, median oxygen uptake at the anaerobic threshhold was 8.25 ml/kg/min. Flow was measured by a flow wire (0.018 inch) positioned in a pulmonary artery branch with a diameter of 3-8 mm determined by intravascular ultrasound before. Acetylcholine infusion was adjusted to 10(-6), 10(-5) and 10(-4) molar concentrations in the pulmonary artery branch. A dose dependent increase in flow between 64 to 140% was seen in 8 out of 10 patients. We conclude: Acetylcholine mediated vasodilation is found in patients with CHF and elevated pulmonary vascular resistances.
The Cardiac Support Device (CSD), a preformed-knitted polyester device surgically placed over the cardiac ventricles, prevents left ventricular (LV) remodeling and improves LV ejection fraction (EF) in dogs with heart failure (HF). This study was designed to examine the safety of the CSD in patients with advanced HF. As of December 31, 1999, the CSD was implanted into 22 patients with myocardial disease. Ten patients had concomitant mitral valve repair, two patients had valve replacement (one patient aortic and one patient mitral), one patient had LV assist device (LVAD) placement, and eight patients received only the CSD. The CSD was placed while on bypass with the heart beating, attached to the epicardium groove, and tailored anteriorly to snugly fit the ventricles. There were no intraoperative deaths or complications. Two patients died early from non-CSD-related causes 4 and 23 days postoperatively; one late death occurred. Of the remaining 19 patients, none had any CSD-related adverse events during an average 3.5 +/- 0.4 month follow-up. All patients had completed 3-month follow-up. No patients had evidence of constrictive and/or restrictive physiology. Mitral valve regurgitation (MVR) improved in all patients. [table: see text] Initial findings indicate that the CSD is safe and improves heart failure symptoms and LV function. Additional studies and longer follow-up are needed to confirm these results.